AIM
BCRX icon

Assured Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Assured Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,818
Closed -$72K – 139
2019
Q1 		$72K Buy
+8,818
New +$75.5K ﹤0.01% 928
2018
Q4 		– Sell
-5,282
Closed -$40K – 1131
2018
Q3 		$40K Buy
+5,282
New +$35.5K ﹤0.01% 1103

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Assured Investment Management's BCRX Position: Q2 2019 in Review

Assured Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 8,818 shares — an estimated $72K sold.

Assured Investment Management first reported a position in BCRX in Q3 2018 and held it in 2 quarters. The position peaked at $72K in Q1 2019. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

  • Assured Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Assured Investment Management sold 8,818 BioCryst Pharmaceuticals shares in Q2 2019, an estimated $72K.
  • Assured Investment Management first reported a position in BioCryst Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Assured Investment Management's BioCryst Pharmaceuticals position peaked at $72K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.